Poly(ADP-ribose) Polymerase Inhibitors
"Poly(ADP-ribose) Polymerase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Chemicals and drugs that inhibit the action of POLY(ADP-RIBOSE)POLYMERASES.
| Descriptor ID |
D000067856
|
| MeSH Number(s) |
D27.505.519.389.739 D27.505.954.248.692
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Poly(ADP-ribose) Polymerase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Poly(ADP-ribose) Polymerase Inhibitors".
This graph shows the total number of publications written about "Poly(ADP-ribose) Polymerase Inhibitors" by people in this website by year, and whether "Poly(ADP-ribose) Polymerase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2017 | 6 | 2 | 8 |
| 2018 | 8 | 1 | 9 |
| 2019 | 2 | 2 | 4 |
| 2020 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Poly(ADP-ribose) Polymerase Inhibitors" by people in Profiles.
-
Impact of COVID-19 on medical treatment patterns in gynecologic oncology: a MITO group survey. Int J Gynecol Cancer. 2021 10; 31(10):1363-1368.
-
Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses In Vitro. mBio. 2021 01 19; 12(1).
-
Role of Poly(ADP-ribose) Polymerase (PARP1) in Viral Infection and its Implication in SARS-CoV-2 Pathogenesis. Curr Drug Targets. 2021; 22(13):1477-1484.
-
Poly(ADP-Ribose) Polymerase Inhibition in Acute Lung Injury. A Reemerging Concept. Am J Respir Cell Mol Biol. 2020 11; 63(5):571-590.
-
Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide. Biosci Rep. 2020 10 30; 40(10).
-
Coronavirus infection and PARP expression dysregulate the NAD metabolome: An actionable component of innate immunity. J Biol Chem. 2020 12 25; 295(52):17986-17996.
-
PARP-inhibitors in a non-oncological indication as COVID-19: Are we aware about its potential role as anti-thrombotic drugs? The discussion is open. Biomed Pharmacother. 2020 Oct; 130:110536.
-
Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer. Eur J Cancer. 2020 09; 136:99-106.
-
Repositioning PARP inhibitors for SARS-CoV-2 infection(COVID-19); a new multi-pronged therapy for acute respiratory distress syndrome? Br J Pharmacol. 2020 08; 177(16):3635-3645.
-
Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use? Eur J Cancer. 2020 09; 136:1-3.